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The spread of multidrug-resistant isolates of Mycobacterium tuberculosis requires the
discovery of new drugs directed to new targets. In this study, we investigated the activity
of two boldine-derived alkaloids, seconeolitsine (SCN) and N-methyl-seconeolitsine (N-
SCN), against M. tuberculosis. These compounds have been shown to target DNA
topoisomerase I enzyme and inhibit growth of Streptococcus pneumoniae. Both SCN
and N-SCN inhibited M. tuberculosis growth at 1.95–15.6 µM, depending on the strain.
In M. smegmatis this inhibitory effect correlated with the amount of topoisomerase
I in the cell, hence demonstrating that this enzyme is the target for these alkaloids
in mycobacteria. The gene coding for topoisomerase I of strain H37Rv (MtbTopoI)
was cloned into pQE1 plasmid of Escherichia coli. MtbTopoI was overexpressed with
an N-terminal 6-His-tag and purified by affinity chromatography. In vitro inhibition of
MtbTopoI activity by SCN and N-SCN was tested using a plasmid relaxation assay.
Both SCN and N-SCN inhibited 50% of the enzymatic activity at 5.6 and 8.4 µM,
respectively. Cleavage of single-stranded DNA was also inhibited with SCN. The effects
on DNA supercoiling were also evaluated in vivo in plasmid-containing cultures of
M. tuberculosis. Plasmid supercoiling densities were−0.060 in cells untreated or treated
with boldine, and −0.072 in 1 × MIC N-SCN treated cells, respectively, indicating that
the plasmid became hypernegatively supercoiled in the presence of N-SCN. Altogether,
these results demonstrate that the M. tuberculosis topoisomerase I enzyme is an
attractive drug target, and that SCN and N-SCN are promising lead compounds for
drug development.
Keywords: Mycobacterium tuberculosis, DNA topoisomerase I inhibitor, DNA supercoiling, N-methyl-
seconeolitsine, seconeolitsine, antituberculosis activity, drug discovery
INTRODUCTION
Mycobacterium tuberculosis is the causative agent of tuberculosis (TB), a major global health issue.
In 2016, an estimated 6.3 million people developed TB, 1.3 million of HIV-negative people and
374,000 HIV-positive people died because of TB (World Health Organization, 2017). Nowadays,
the recommended treatment for drug-susceptible TB is a 6-month regime of four first-line drugs:
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isoniazid, rifampicin, ethambutol, and pyrazinamide. Failures
in drug supply and patients’ lack of adherence to treatment
(among other factors) have resulted in the emergence of
resistance to anti-TB drugs. Multidrug-resistant TB (MDR-TB)
is characterized by resistance to both rifampicin and isoniazid.
Treatment of these strains takes longer and requires additional
drugs that are more toxic and less effective. In fact, in 2016,
a total of 490,000 people developed MDR-TB globally, leading
to an estimated 240,000 deaths. In addition, an estimated 6.2%
of MDR-TB cases progressed into extensively drug-resistant TB
(XDR-TB), defined as MDR-TB with additional resistance to a
fluoroquinolone and at least one of three injectable second-line
drugs (amikacin, kanamycin, or capreomycin).
Given these facts, new anti-TB drugs are urgently needed.
Rifampicin, the most effective anti-TB drug, was introduced into
clinical practice in the 1960s. Since then only one drug has been
developed, bedaquiline, which recently was approved for MDR-
TB treatment (Palomino and Martín, 2013). Even though when
new drug candidates are emerging from the pipeline, and some
are undergoing clinical trials (Zumla et al., 2014), investigation
of new anti-TB drugs needs to continue. In order to avoid cross-
resistance with already existing drugs, it is necessary to identify
and characterize new targets for anti-TB drugs (Sharifi-Rad et al.,
2017).
The DNA supercoiling level is an essential parameter
of bacteria, given that it is a critical component of DNA
replication, transcription, and recombination (Champoux, 2001).
An adequate level of DNA supercoiling is maintained by DNA
topoisomerase enzymes. These enzymes act on double-strand
DNA, cleaving either both strands (type II enzymes) or one of
the DNA strands (type I enzymes) allowing the intact segment
to pass through. The cleaved DNA is then resealed before
being released. DNA topoisomerase I (TopoI) has been proposed
as a new antibacterial target (Tse-Dinh, 2009). Some natural
compounds inhibited in vitro the enzymatic activity of this
enzyme from Yersinia pestis and Escherichia coli, and were shown
to enhance DNA cleavage (Cheng et al., 2007, 2013). Among
them was a phenanthrene alkaloid able to inhibit the relaxation
activity of E. coli TopoI, although no significant inhibition in cell
growth was observed (Cheng et al., 2007). We have established
TopoI as a new drug target in Streptococcus pneumoniae
and described two novel alkaloid compounds: seconeolitsine
(SCN) and N-methyl-seconeolitsine (N-SCN), derived from
boldine. Both compounds inhibited S. pneumoniae TopoI activity
in vitro at concentrations equivalent to those necessary to
inhibit bacterial growth (∼10 µM) without affecting human
cell viability (García et al., 2011). M. tuberculosis possess two
DNA topoisomerases: one type II enzyme, DNA gyrase, which
is targeted by fluoroquinolone antibiotics (Kumar et al., 2014)
and one type I enzyme, topoisomerase I (MtbTopoI), which is
encoded by Rv3646c (topA) gene. This gene has been shown to be
essential for M. tuberculosis growth (Kumar et al., 2014).
The aim of the present study was to investigate these
two boldine-derivative alkaloids as potential inhibitors of the
MtbTopoI enzyme, a scarcely explored drug target. SCN and
N-SCN inhibited growth of M. tuberculosis at relatively low
concentrations and also inhibited MtbTopoI activity in vitro. In
addition, their effects on DNA supercoiling were evaluated in
plasmid-containing cultures of M. tuberculosis.
MATERIALS AND METHODS
Bacterial Strains, Growth Conditions and
Determination of Minimal Inhibitory
Concentrations (MICs)
The reference laboratory strain M. tuberculosis H37Rv (ATCC
25618) and a panel of eight genetically distinct clinical strains
of M. tuberculosis were used for drug susceptibility testing. This
included strain GC1237, a highly transmissible strain of the
Beijing lineage. A derivative of the H37Rv strain containing
plasmid vector pSUM36 (Ainsa et al., 1996) was used for
testing the in vivo effect of alkaloids on DNA supercoiling. To
determine the mechanism of action of topoisomerase inhibitors,
Mycobacterium smegmatismc2155 (Snapper et al., 1990) was used
along with its derivative MsPptrtopoI conditional knock-down
mutant (Ahmed et al., 2015), in which levels of topoisomerase
I (MsTopoI) can be reduced by addition of anhydrotetracycline
(ATc). All strains were grown in Middlebrook 7H9 broth (Becton
Dickinson) supplemented with 10% ADC (Becton Dickinson)
and 0.05% Tween 80 (Sigma). Kanamycin (50 mg/L) was added to
ensure the maintenance of plasmid pSUM36. Minimal inhibitory
concentrations (MICs) were determined by microdilution as
previously reported for M. tuberculosis (Palomino et al., 2002);
MICs of drugs for M. smegmatis were determined by the
same method except that plates were incubated for 3 days.
The MIC was defined as the lowest concentration of drug
that prevented change of resazurin from its oxidized form
(blue) into the reduced one (pink), which is indicative of
bacterial growth. Imipramine, a well-known topoisomerase-
poison described previously (Godbole et al., 2015) was included
as a control. For the time-kill kinetics experiments, a bacterial
inoculum of 107 CFU/ml was incubated in the presence of
inhibitory concentrations of N-SCN (8×MIC) for 24 h at 37◦C;
then, the culture was serially diluted in order to determine the
number of viable bacteria, by plating on Middlebrook 7H10
plates; relative CFUs in comparison with untreated control
cultures were determined.
Cloning and Expression of
M. tuberculosis topA in Escherichia coli
The Rv3646c (topA) gene from M. tuberculosis was amplified by
PCR using 0.5 µg of chromosomal DNA from M. tuberculosis
H37Rv strain as a template and 1 µM each of the following
synthetic oligonucleotide 5′-phosphorylated primers: TopAT-
bUP2 (5′-ATGGCTGACCCGAAAACGAAGGG-3′) and TopA-
TbDOWN2 (5′-cgcgcgcatgcCTAGTCGCGCTTGGCTGCC-3′).
The latter including a PaeI restriction site (lowercase underlined).
The sequence of primer TopATbUP2 contained the ATG
initiation codon and the sequence of TopATbDOWN contained
the TAG stop codon of Rv3646 (both upper-case underlined).
Amplification was achieved using an initial cycle of 2 min
denaturation at 94◦C, followed by 30 s annealing at 55◦C, and
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a 3 min polymerase extension with Platinum Taq Polymerase
high-fidelity (Invitrogen) at 68◦C. This was followed by 34
cycles of 30 s at 94◦C, 30 s at 55◦C and 3 min at 68◦C
followed by slow cooling at 8◦C. After completing amplification,
excess oligonucleotides were removed using the QIAquick
PCR Purification Kit (QIAGEN). The amplicon was digested
with PaeI, cloned into plasmid vector pQE1 (TAGZyme,
Qiagen) digested with PaeI + PvuII (blunt ends), resulting in
recombinant plasmid pQE-MtbTopA that was introduced into
E. coli XL1Blue. Sequencing with oligonucleotides pQE-seq3
(5′-AGCTAGCTTGGATTCTCACC-3′) and pQE-seq5 (5′-GA
GGCCCTTTCGTCTTCA-3′) was performed to confirm that no
mutation was introduced during cloning. The pQE1 vector/XL1
host cloning system permits the hyperproduction of 6 × His-
tagged recombinant proteins encoded by genes placed under the
control of a phage T5 promoter and two lac operator sequences.
A culture of E. coli XL1/pQE-MtbTopA was grown at 37◦C in 2 L
of LB medium containing 100µg/ml of ampicillin until it reached
an OD620 of 0.6. Cells were induced with 1mM Isopropyl-β-D-
thiogalactoside (IPTG) for 3 h, harvested by centrifugation and
suspended in 50 ml of buffer A (50 mM NaH2PO4 pH 8, 300 mM
NaCl, 1 mM PMSF) containing 10 mM imidazole. Triton X100
was added to a final concentration of 0.25%, and the solution was
frozen at−80◦C then defrosted on ice. Cells were then incubated
with lysozyme (1 mg/ml) at 4◦C for 60 min with lysozyme and
sonicated for 100 s (5 times for 20 s, with 1 min cooling between
each burst) in a Sonifier B-12 (Branson Co., Connecticut). The
crude extract was centrifuged at 10.000 × g for 20 min and
the resulting supernatant filtered using a 0.45 µm Millipore
Millex R©HA filter. The MtbTopoI protein was purified by affinity
chromatography in 1 ml Ni-NTA (QIAGEN) column attached
to an ÄKTA FPLC system using the standard manufacturer
protocol for this column. The column was equilibrated with 10
column volumes of buffer A. Non-specifically bound proteins
were removed with a 20 column volume of 10–60 mM imidazole
in buffer A. Specifically bound proteins were eluted with a 40
column volume gradient of 60–350 mM imidazole. Fractions of
2 ml were collected and analyzed by SDS-10% polyacrylamide gel
electrophoresis followed by Coomassie blue staining. Fractions
containing a protein of the expected size, which had eluted at
around 100 mM imidazole were dialyzed against buffer B (50 mM
NaH2PO4 pH 8, 100 mM NaCl, 0.5 mM DTT, 50% glycerol).
The purified MtbTopoI protein was stored at−20◦C and thereby
remained active for at least 12 months.
Relaxation of pBR322 in Vitro by
M. tuberculosis TopoI and Cleavage
Assay
Reactions were carried out using 0.5 µg of supercoiled plasmid
pBR322 in 200 µl of a buffer containing 50 mM Tris HCl pH 8,
20 mM KCl, 10 mM MgCl2, 0.5 mM DTT and 30 µg BSA/ml.
After 1 h incubation at 37◦C in the presence on MtbTopoI, the
reaction was terminated by incubation at 37◦C for 2 min after
adding EDTA to a final concentration of 50 mM followed by
an incubation of 1 h at 37◦C in the presence of 1% SDS and
100 µg/ml proteinase K. When required, samples were ethanol
precipitated and suspended in H2O. Reaction products were
analyzed by electrophoresis in 1.2% agarose gels in 1 × TAE
at 18 V for 16 h. In order to test the effect of drugs against
the MtbTopoI-mediated relaxation of pBR322, the enzyme was
pre-incubated with these compounds for 10 min at 4◦C in
a final volume of 20 µl. Electrophoresis was carried out in
gels in the presence and absence of ethidium bromide (EtBr).
Quantification of DNA was performed by densitometers of EtBr
stained agarose gels (Quantity One, Bio-Rad Laboratories). To
calculate MtbTopoI activity, the amount of the CCC form was
measured and the value divided by the total amount of DNA in
each well. The mean IC50 (n = 3) was defined as the concentration
of drug required to achieve a 50% reduction of enzymatic activity.
For the cleavage assay, a 5′-biotin-labeled 32-mer olig-
onucleotide (5′-CAGTGAGCGAGCTTCCGCTTGACATCCCA
ATA-3′), which contains the strong topoisomerase site of
mycobacterial TopoI, was used as substrate (Godbole et al.,
2015). Reaction mixtures containing 1 unit of MtbTopoI in
the same buffer as above were pre-incubated with SCN for
10 min at 4◦C. Then, 0.1 pmol of the DNA substrate were
added and the mix was incubated for 30 min at 30◦C. Reactions
were terminated by adding 45% formamide dye and heating
at 95◦C for 5 min. Samples were resolved on 12% denaturing
7 M urea/PAGE using 1 × TBE as running buffer at 300 V.
DNAs were transferred to Hybond-N+ membrane (Amersham)
using the Trans-blot cell (Bio-Rad) in 1 × TAE buffer according
to the manufacturer’s instructions and the blots were UV-
cross-linked. Detection was performed by autoradiography using
chemiluminescent nucleic acid detection module from Thermo
Fisher Scientific. Enzyme activity was determined by relative
quantification of band intensities with ImageLab software.
Activity of Alkaloids on DNA Supercoiling
in M. tuberculosis Cultures
Cultures of 50 ml of M. tuberculosis H37Rv containing the
plasmid vector pSUM36 were grown until OD600 of 0.4 was
reached, which corresponded to a density of 1.7 × 107 bacterial
cells/ml. The culture was split into three fractions, one of which
was left untreated, while the other two were either treated with
boldine at 500 µM (corresponding to 1 × MIC) or SCN at
15.6 µM (corresponding to 1 × MIC). After 4 h at 37◦C, total
DNA was extracted from half of each fraction as described
previously (Ferrándiz et al., 2010). At 24 h the other half of each
fraction was processed as above. DNA samples were suspended
in 30 µl of distilled water and kept at −20◦C until analyzed in
two-dimensional agarose gels.
Analysis of the Topology of Covalently
Closed Circles
Circular DNA molecules were analyzed in neutral/neutral two-
dimensional agarose gels, a technique that allows to separate
DNA molecules by mass and shape. The first dimension
was run at 1.5 V/cm in a 0.4% agarose (Seakem; FMC
Bioproducts) gel in Tris-borate-EDTA (TBE) buffer for 17−19 h
at room temperature. The second dimension was run at
7.5 V/cm in 1% agarose gel in TBE buffer for 7−9 h at 4◦C.
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Chloroquine (Sigma) was added to the TBE buffer of both
the agarose gel and the running buffer. After electrophoresis,
gels were subjected to Southern hybridization. A 177-pb
probe was obtained by PCR amplification of the kanamycin-
resistance gene of plasmid pSUM36 (Ainsa et al., 1996)
with oligonucleotides PSUM36FBIOT 5′-TCGGCAGGAGCAA
GGTGAGATGA-3′ (biotinylated at 5′) and PSUM36R 5′-CC
TGTCCGGTGCCCTGAATGAA-3′. This probe was used on
the nylon membranes (Inmobylon NY+, Millipore) onto
which the two-dimensional agarose gels had been transferred.
Chemiluminescent detection of DNA was performed with the
Phototope R© -Star kit (New England Biolabs). Images were
captured in a VersaDoc MP400 system and analyzed with the
Quantity One program (Bio-Rad).
RESULTS
Inhibition of M. tuberculosis Growth by
Alkaloids
We first tested the susceptibility of several M. tuberculosis isolates
to boldine and its derivatives SCN and N-SCN (Table 1).
In general, M. tuberculosis strains were more susceptible to
boldine, SCN and N-SCN than what we reported previously
for streptococci (data from García et al., 2011, are included
in Table 1 for comparison). Susceptibility to boldine was low,
with MIC values ranging from 31.25 to >500 µM, in agreement
with previous reports of the low anti-TB activity of this alkaloid
(Guzman et al., 2010). Boldine derivatives SCN and N-SCN
showed a much stronger antimicrobial activity, resulting in a
minimum of a fourfold decrease in the MIC. For some clinical
strains, such as HMS1292 (Table 1), the MIC of N-SCN was
32-times lower than that of the parent compound boldine,
reaching as low as 1.95 µM, the lowest MIC we have detected. We
speculated that sequence polymorphisms in the gene encoding
MtbTopoI could explain the high susceptibility to alkaloids
shown by some isolates, however, after sequencing Rv3646c
alongside flanking regions in these strains, no polymorphisms
were found. Hence, permeability, differences in the nucleoid-
associated protein repertoire, or other unidentified mechanisms
must be involved in basal susceptibility of mycobacteria to SCN
and N-SCN.
Cloning of the Gene Coding the DNA
Topoisomerase I of M. tuberculosis
H37Rv
The MtbTopoI is encoded by topA gene (Rv3646c) in
M. tuberculosis H37Rv genome. The enzyme consists of 934
amino acids and has an estimated molecular weight of 102.3 kDa
(Cole et al., 1998). The topA gene was amplified by PCR
from M. tuberculosis H37Rv chromosomal DNA with specific
oligonucleotides and cloned into the E. coli plasmid pQE-1
rendering plasmid pQE-MtbTopoI, which carries the Met-
(His)6-Gln-MtbTopoI fusion protein under the control of T5
promoter. This plasmid was introduced into E. coli XL1-Blue and
its T5 promoter was induced by IPTG leading to overexpression
TABLE 1 | Susceptibilities of bacterial isolates to boldine and its alkaloid
derivatives.
Bacterial isolate MIC (µM)
Boldine N-SCN SCN
S. pneumoniae R6 1000 16 16
S. pneumoniae ATCC 6303T 1000 16 16
S. mitis NCTC 12261T 1000 16 16
M. tuberculosis H37Rv >500 15.6 15.6
M. tuberculosis GC 1237 31.25 7.8 7.8
M. tuberculosis HMS1553 31.25 1.95 3.9
M. tuberculosis HMS 1292 62.5 1.95 7.8
M. tuberculosis HMS1278 >250 7.8 15.6
M. tuberculosis HMS 1498 31.25 3.9 7.8
M. tuberculosis HMS 1500 >250 7.8 15.6
M. tuberculosis HMS 1536 >250 7.8 15.6
M. tuberculosis HMS 1546 >250 7.8 7.8
of a protein with an apparent molecular weight of 100 kDa
(Figure 1A). This is in agreement with the expected size of
the fusion protein (102.3 kDa for MtbTopoI + 1.23 kDa for
the N-terminal fusion). Although other proteins co-eluted with
MtbTopoI (Figure 1B) they did not appear to interfere with the
DNA relaxation activity of MtbTopoI on pBR322. The total yield
of purification was 0.160 mg of MtbTopoI per 2 l culture. The
final concentration was 8 mg/l and the recombinant MtbTopoI
had a specific relaxation activity of 1.25 × 106 units/mg (see
below).
To test the DNA relaxation activity of MtbTopoI, covalently
closed negatively supercoiled (CCC) pBR322 plasmid (0.86 nM)
was incubated in the presence of different amounts of the
purified enzyme and the reaction products analyzed in mono-
dimensional agarose gels as described (García et al., 2011).
MtbTopoI activity converted the CCC plasmid into topoisomers
with different degrees of supercoiling that were observed as
discrete bands in a gel run in the absence of EtBr (Figure 1C). As
expected, all relaxed topoisomers (RC) migrated as a single band
when the gel was run in the presence of saturating concentrations
of EtBr (Figure 1D). A unit of MtbTopoI enzymatic activity was
defined as the amount of enzyme being able to relax 50% of the
CCC substrate in 1h at 37◦C. This corresponded to 8 ng (3.6 nM)
of purified enzyme.
Inhibition of M. tuberculosis TopoI
Activity by Alkaloids
We have previously reported inhibition of growth and inhibition
of S. pneumoniae TopoI by 18 semisynthetic compounds derived
from the natural alkaloid boldine (García et al., 2011). Out of
these, two phenanthrene alkaloids, N-SCN and SCN, showed the
greatest inhibition of S. pneumoniae growth. These were selected
to be assayed for inhibition of MtbTopoI. While boldine did
not inhibit the enzyme, even at concentrations up to 500 µM
(data not shown), MtbTopoI relaxation activity was inhibited in
a concentration-dependent manner with N-SCN (Figure 2A),
with IC50 values (average ± SD) of 5.6 ± 0.8 µM (n = 3).
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FIGURE 1 | Expression, purification and activity of Mycobacterium tuberculosis Topoisomerase I. (A) Cultures of Escherichia coli XL1Blue containing pQE1-MtbTopA
were grown in LB medium and induced with IPTG at the indicated times. Crude extract samples of 10 µl were electrophoresed in a SDS-12% polyacrylamide gel.
The polypeptides were visualized by Coomassie Blue staining. (B) Fractions extracted from a Ni-NTA column that showed topoisomerase I activity. (C,D) Plasmid
pBR322 (0.5 µg) was incubated with the indicated amounts of purified MtbTopoI for 1 h at 37◦C. OC, relaxed open circles; CCC, covalently closed circles; RC
relaxed circular plasmids forms. Mw, molecular mass standard. (C) Agarose gel run in the absence of EtBr. (D) The same samples as in C were run in the presence
of 1 µg/ml of EtBr.
The inhibition by SCN was comparable, with IC50 values of
8.4± 0.3 µM (n = 3) (Figure 2B). A good correlation between the
inhibition of MtbTopoI activity and the inhibition of cell growth
was observed for these compounds. Additionally, inhibition of
cleavage of a 32-mer single-stranded DNA with SCN was detected
(Figure 2C). Significant decreases (P < 0.05) of 1.7- and 1.9-fold
(Figure 2D) in the amount of the 19-mer product were observed
at 80 µM SCN when compared with the untreated sample and
5 µM treated samples, respectively. These results imply that
MtbTopoI is indeed the in vivo target of SCN and N-SCN.
Targeting ofM. tuberculosis TopoI in Vivo
With N-SCN
Evidence of the inhibition in vivo of MtbTopoI by N-SCN
was obtained from the analysis of topoisomer distribution of
the mycobacterial plasmid vector pSUM36 by two-dimensional
agarose gel electrophoresis, a suitable approach for studying
supercoiling levels (Ferrándiz et al., 2010). Treatment of
pSUM36-containing M. tuberculosis cultures with N-SCN at
1 × MIC resulted in a 20% increase of plasmid supercoiling
(Figure 3). Supercoiling density (σ) was −0.060 in the non-
treated sample and in 1 × MIC boldine-treated sample, and
−0.072 in 1 × MIC N-SCN-treated sample, indicating that
plasmids became hypernegatively supercoiled. Although direct
extrapolation from observations made in small plasmids is not
completely equivalent to the bacterial chromosome, our results
indicate that supercoiling significantly increases in the presence
of N-SCN, and support the model that MtbTopoI is its target
in vivo.
Elucidation of the Mechanism of Action
of SCN and N-SCN in Mycobacteria
Mycobacterium smegmatis was used as a model for determining
the mechanism of action of SCN and N-SCN in mycobacteria.
The MsPptrtopoI strain of M. smegmatis is a conditional knock-
down strain which normally produces 1.5 less MsTopoI enzyme
than wild type cells, and this level can be reduced further by 2.5
times in the presence of ATc (Ahmed et al., 2015). We observed
that, accordingly to the reduction in the levels of MsTopoI
enzyme, the MIC of SCN and N-SCN against M. smegmatis
strains decreased (Table 2), whereas in contrast, the MIC of
imipramine (a well-known topoisomerase poison; Godbole et al.,
2015) increased. These experiments suggested that, since reduced
levels of MsTopoI render the bacteria more susceptible to SCN
and N-SCN, MsTopoI would be the target in vivo of these two
inhibitors.
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FIGURE 2 | Inhibition of M. tuberculosis topoisomerase I by SCN and N-SCN.
(A,B) Supercoiled pBR322 (0.5 µg) was treated with 1 unit of purified
MtbTopoI in 200 µl reactions containing N-SCN, SCN, or boldine at the
concentrations (µM) indicated. Mw, molecular mass standard; S, covalently
closed supercoiled pBR322 used as substrate. (C) One unit of MtbTopoI was
pre-incubated with SCN at the indicated concentrations, then 0.1 pmol of
5′-biotin-labeled 32-mer oligonucleotide was added and the reaction was
continued for 30 min. The products were resolved in 12% denaturing PAGE.
(D) Quantification of the 19-mer cleavage product. The values (mean ± SD) of
three independent experiments are shown. ∗ indicates statistical significance
by Student T-test P < 0.05.
In order to corroborate this finding, the kill time kinetics
of inhibitory concentrations of N-SCN on M. smegmatis strains
was determined after time. We compared the survival of the
conditional knock-down mutant of M. smegmatis (MsPptrtopoI
strain) with that of its corresponding complemented strain,
which harbored a plasmid-encoded copy of the M. smegmatis
topA gene. The complemented strain survived better than the
parental one in the presence of 8-times the MIC of N-SCN, which
can be attributed to a higher content of MsTopoI enzyme in the
complemented strain (Figure 4).
DISCUSSION
The use of antimicrobials is one of the most effective ways to
combat infectious diseases. In the case of TB, effective drugs
are scarce: these are just four first-line drugs used in the
standard treatment of TB caused by drug susceptible strains.
Meanwhile, the incidence of drug resistant TB is increasing,
despite the fact that the overall incidence of TB is decreasing
slightly. This leaves a very limited number of therapeutic options.
This situation has prompted investigation into new drugs, new
targets, and new therapies for curing TB (Zumla et al., 2013,
2014). Natural products have been an extraordinary source of
antimicrobials in general (Newman and Cragg, 2012; Cragg
and Newman, 2013) and of anti-TB compounds in particular
(Salomon and Schmidt, 2012). Natural products frequently
lack some of the pharmacological properties desirable for a
drug, making it necessary to develop semisynthetic products by
chemical modifications. Boldine is a natural alkaloid produced
by the tree Peumus boldus and has no significant antimicrobial
activity. We have reported that two boldine derivatives (SCN and
N-SCN) showed significant anti-pneumococcal activity (García
et al., 2011). In this study, we have characterized the anti-
mycobacterial activity of these drugs, along with the inhibitory
activity on their potential target, the topoisomerase I enzyme.
Mycobacterium tuberculosis strains were susceptible to low
concentrations of SCN or N-SCN. The reference strain H37Rv
was the least susceptible strain, but even here the MIC was
15.6 µM (equivalent to 5 µg/ml). Other clinical isolates
were susceptible at concentrations of 1.95 µM (equivalent to
0.65 µg/ml). Although these values are greater than the MICs
of the most potent anti-TB drugs, isoniazid and rifampicin, they
are in the same league as the MICs of ethambutol (another first-
line antituberculosis drug) for strains susceptible to this drug
(Christianson et al., 2014). The variation in the MICs among the
various M. tuberculosis clinical strains could be related to their
repertoire of nucleoid-associated proteins. For example, it has
been shown that one of these proteins, HU, specifically regulates
MtbTopoI activity (Ghosh et al., 2015). In any case, the range of
MICs observed with SCN and N-SCN coincides with the IC50
values of the MtbTopoI enzyme (ca. 8 µM). This suggests that
both SCN and N-SCN can efficiently cross the mycobacterial
cell wall, which is a highly impermeable barrier that in general
limits the in vivo activity of inhibitors shown to be potent enzyme
inhibitors in vitro.
The comparison of MICs for S. pneumoniae (García et al.,
2011) and M. tuberculosis showed that the latter is more
susceptible to the Topo I inhibitors SCN and N-SCN. This
fact could be related to the differences in the set of DNA
topoisomerases available to each species. Both species have a
single type I enzyme, but while S. pneumoniae possesses two type
II enzymes (gyrase and topoisomerase IV), M. tuberculosis lacks
topoisomerase IV (which carries out efficient DNA relaxation in
addition to decatenation). This leaves gyrase as the only type II
enzyme in M. tuberculosis (Manjunatha et al., 2002; Kumar et al.,
2012). Altogether, this enzyme complement must maintain the
appropriate level of chromosome supercoiling; in M. tuberculosis,
gyrase carries out the dual function of both negative supercoiling
and decatenation (Cole et al., 1998). Therefore, in the absence
of topoisomerase IV, the only mycobacterial enzyme responsible
for DNA relaxation is Topo I. Consequently, the inhibition
of this enzyme by SCN and N-SCN would be more lethal
in M. tuberculosis than in S. pneumoniae. Therefore, it would
be worthwhile to investigate the antimicrobial activity of SCN
Frontiers in Microbiology | www.frontiersin.org 6 July 2018 | Volume 9 | Article 1659
fmicb-09-01659 July 24, 2018 Time: 12:36 # 7
García et al. Inhibition of M. tuberculosis DNA Topoisomerase I
FIGURE 3 | Treatment with N-SCN causes hypernegative supercoiling in plasmid DNA. An exponentially growing culture of the M. tuberculosis H37Rv strain carrying
plasmid pSUM36 was treated at OD600 = 0.4 with N-SCN or boldine at 1 × MIC. Purified plasmid DNA from samples collected at 24 h after treatment was
subjected to two-dimensional agarose gel electrophoresis in the presence of 5 µg/ml chloroquine in the first dimension and 15 µg/ml in the second dimension. An
empty arrowhead indicates the topoisomer that migrated with 1Lk = 0 in the second dimension. A black arrowhead indicates the most abundant topoisomer. The
corresponding supercoiling density (σ) is indicated below each autoradiogram.
FIGURE 4 | Killing activity of inhibitory concentrations of N-SCN on
M. smegmatis. After a 24-h treatment with an inhibitory concentration of
N-SCN (8 × MIC), the complemented knock-down strain MsPptrtopoI strain
(gray bars) was killed at a lower rate than its non-complemented parental
strain (white bars); this difference was significant (P < 0.05).
The mean ± standard error of the mean from at least three independent
replicates is shown.
and N-SCN in other bacterial pathogens, which also lack
topoisomerase IV, such as Helicobacter pylori (Debowski et al.,
2012).
The topoisomer distribution of the plasmid pSUM36 under
control conditions showed a mean superhelical density of−0.060,
a figure compatible with that reported for E. coli (Deng et al.,
2005) and S. pneumoniae (Ferrándiz et al., 2010, 2016). Under
treatment with N-SCN at 1 × MIC, a modest increase (20%) in
pSUM36 superhelical density was observed in M. tuberculosis.
This value is lower than the >58% observed due to treatment
TABLE 2 | Correlation between MICs of SCN and N-SCN and levels of MsTopoI.
MICs (µM)
M. smegmatis
strain
Levels of
TopoI
Imipramine N-SCN SCN Boldine
mc2155 +++ 125–200 100 30–60 >300
MsPptrtopoI ++ 175–300 50 15–30 >300
MsPptrtopoI+ ATc + 350 25 15 >300
ATc, anhydrotetracycline was added at a concentration of 200 ng/ml.
Topoisomerase I levels in M. smegmatis strains: +++: wild type levels; ++: 1.5
times below wild type levels; +: 2.5 times below MsPptrtopoI levels. Estimations
according to Ahmed et al. (2015).
of S. pneumoniae with SCN at 1 × MIC, but close to the ±20%
variation displayed during normal E. coli cell growth (Drlica,
1992). These results may indicate that, given the scarcity of the
DNA topoisomerase complement of M. tuberculosis, the capacity
of this bacterium to tolerate changes in supercoiling levels is more
limited than with E. coli or S. pneumoniae.
The investigation of MtbTopoI as a drug target began
very recently; when its requirement for cell survival was
demonstrated (Ahmed et al., 2014). Until now, several MtbTopoI
inhibitors have been discovered. The small molecule amsacrine,
a eukaryotic type II topoisomerase poison used as an anti-
neoplastic, is an inhibitor of this enzyme in M. tuberculosis
(Godbole et al., 2014). Imipramine and norclomipramine are two
drugs used clinically as antidepressants that also inhibit MtTopoI
(Godbole et al., 2015). All these compounds are considered as
topoisomerase poisons, since they perturb the cleavage–religation
equilibrium and result in the accumulation of enzyme–DNA
covalent adducts, which ultimately kill the bacterial cell (Nagaraja
et al., 2017). There are other classes of compounds that directly
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inhibit TopoI (Sandhaus et al., 2016, 2018). SCN and N-SCN
form part of this last class of compounds. Mechanistically, both
types of inhibitors can be distinguished because increases in the
levels of TopoI lead to a decrease in the MIC in the case of
topoisomerase poisons, or to an increase in the MIC in the case
of topoisomerase inhibitors (Nagaraja et al., 2017). In the case of
SCN and N-SCN, the results we have obtained in this study using
mycobacterial strains and in our previously published study with
S. pneumoniae (García et al., 2011) indicate that they belong to
the topoisomerase inhibitors class, not to topoisomerase poisons,
since in both microorganisms we detected that increases in
the quantity of TopoI corresponded with increases of their
MICs. In fact, we showed that the inhibitory effect exerted
by these alkaloids was enhanced prior to DNA binding, and
in consequence, avoidance of DNA binding resulted in strong
inhibitory effects (García et al., 2011).
Concerning toxicity, however, given the potent activity of
amsacrine on mammalian TopoII, which results in cell death, it
is unlikely that this compound could be used clinically against
M. tuberculosis without further chemical modifications. We have
reported that SCN and N-SCN only partially inhibited human
TopoI at concentrations of 50 µM, well above the inhibitory
concentrations we report in this work for both the enzyme and
the bacterial cultures (García et al., 2011). In addition, SCN and
N-SCN did not cause apoptosis of neutrophil even at 100 µM and
only slightly affected neutrophil survival at this concentration
(García et al., 2011). In summary, the low toxicity of these
compounds makes them very attractive leads for further anti-TB
drug development.
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